Circadian Rhythm Disorders: Causes, Diagnosis, and Treatments

What Is a Circadian Rhythm Disorder?

The circadian system is a biological timekeeping network anchored in the suprachiasmatic nucleus (SCN), a paired cluster of roughly 20,000 neurons in the anterior hypothalamus. The SCN runs on an intrinsic period of approximately 24.2 hours and must be reset daily by environmental "zeitgebers" (time-givers), primarily light. When that resetting fails or the person's schedule conflicts with the clock's output, a circadian rhythm sleep-wake disorder (CRSWD) results. The AASM classifies six main CRSWDs: delayed sleep phase disorder, advanced sleep phase disorder, non-24-hour sleep-wake disorder, irregular sleep-wake rhythm disorder, shift-work disorder, and jet lag disorder [1].

Circadian misalignment depresses melatonin secretion from the pineal gland at the wrong clock time, disrupts the homeostatic sleep pressure curve, and alters cortisol and core body temperature rhythms. A 2019 study in the Journal of Clinical Sleep Medicine (N=2,005) found that adults with confirmed CRSWD had a 2.3-fold higher rate of depression and a 1.8-fold higher rate of metabolic syndrome compared with age-matched controls [2]. These numbers argue for diagnosis and treatment rather than simply tolerating poor sleep.

Delayed Sleep Phase Disorder (DSPD): The Most Common CRSWD

DSPD is defined by a chronic (greater than 3 months) delay of the major sleep episode relative to the desired sleep time, with an inability to advance sleep and wake times on demand. The typical DSPD patient falls asleep between 2 AM and 6 AM and prefers to wake between 10 AM and 2 PM [3]. When forced to rise early for work or school, they accumulate progressive sleep debt and report daytime sleepiness, cognitive slowing, and mood disturbance.

Prevalence estimates range from 0.17% in general population surveys to 3.3% in adolescents, a group whose SCN phase is biologically later than in adults [4]. The gene CRY1 has a dominant-variant allele found in roughly 1 in 75 individuals of European ancestry that lengthens the intrinsic circadian period and predisposes to DSPD [5].

Diagnosing DSPD

Diagnosis requires at minimum a 7-day actigraphy record plus a concurrent sleep diary. Dim-light melatonin onset (DLMO), measured from saliva samples collected every 30 minutes in dim light beginning 6 hours before habitual sleep time, provides the most objective marker. In DSPD patients, DLMO typically occurs after 9 PM, compared with 9 PM or earlier in most adults [6]. The AASM's 2015 clinical practice guideline recommends DLMO measurement when the diagnosis is uncertain [1].

Treating DSPD

The combination of strategically timed light and melatonin produces the largest phase advances. A randomized crossover trial (N=44) published in Sleep Medicine found that 0.5 mg melatonin taken 5 hours before DLMO advanced the sleep phase by 1.5 hours over 4 weeks, significantly more than placebo [7]. Morning bright-light therapy at 2,500 lux for 30 minutes immediately upon waking advances the clock through the photic input pathway to the SCN [8].

Chronotherapy (progressively delaying bedtime by 2 to 3 hours each day until the desired time is reached) can achieve dramatic phase shifts but requires strict light-avoidance protocols afterward and is demanding in practice. For patients who also meet criteria for obstructive sleep apnea, clinicians should treat OSA concurrently because untreated airway obstruction fragments sleep architecture and negates circadian-based interventions [9].

Advanced Sleep Phase Disorder (ASPD): The Early-Bird Syndrome

ASPD is the mirror image of DSPD. Patients sleep from roughly 6 PM to 2 AM and wake spontaneously before 5 AM, unable to delay sleep without severe sleepiness. The condition affects an estimated 1% of middle-aged adults and increases in prevalence with age [10]. Familial ASPD has been linked to mutations in PER2 and casein kinase I delta (CSNK1D) [11].

Evening bright-light therapy (2,500 lux for 2 hours between 7 PM and 9 PM) delays the SCN phase and shifts sleep timing later. A 6-week open-label trial (N=15) published in Chronobiology International reported a mean 2.1-hour delay in habitual sleep onset with nightly 2-hour evening light exposure [12]. Low-dose melatonin (0.5 mg) taken in the morning upon waking may also delay the circadian clock, though evidence is less strong than for DSPD [10].

Shift-Work Disorder: Chronic Circadian Disruption at Scale

An estimated 20% of the U.S. workforce works non-standard hours. Of those workers, 10 to 38% develop shift-work disorder, characterized by insomnia during intended sleep periods and excessive sleepiness during work hours [13]. The disorder is not simply fatigue. A prospective cohort study (N=2,754) published in BMJ Open found that night-shift workers had a 29% higher incidence of type 2 diabetes over 10 years of follow-up compared with day workers, independent of BMI [14].

Pharmacologic Options

The FDA has approved two wake-promoting agents specifically for shift-work disorder:

Modafinil 200 mg taken 1 hour before the night shift. The key trial (N=278) showed modafinil reduced the Epworth Sleepiness Scale score by 2.4 points versus placebo and cut the rate of accidents or near-misses during the commute home by 45% [15].

Armodafinil 150 mg, the R-enantiomer of modafinil, with a longer half-life of 15 hours versus 12 to 14 hours for modafinil. A phase III trial (N=254) demonstrated maintained wakefulness test improvements throughout a 12-hour shift compared with placebo (P<0.001) [16].

Neither agent corrects the underlying circadian misalignment. Timed melatonin (1 to 3 mg) taken 30 minutes before the intended daytime sleep period helps initiate daytime sleep. Blackout curtains, earplugs, and a "do not disturb" protocol for the bedroom during day sleep are non-negotiable environmental controls [1].

Chronic Insomnia: Definition, Prevalence, and First-Line Treatment

Chronic insomnia disorder is defined by the DSM-5 as difficulty initiating or maintaining sleep, or early-morning awakening with inability to return to sleep, occurring at least 3 nights per week for at least 3 months, causing clinically significant daytime impairment [17]. The National Institutes of Health estimates prevalence at 10 to 15% of the adult U.S. population, making it the most common sleep disorder by volume [18].

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment endorsed by the AASM, the American College of Physicians, and the European Sleep Research Society [19]. The ACP's 2016 clinical guideline states: "All adult patients receive CBT-I as the initial treatment for chronic insomnia disorder" [19]. A Cochrane meta-analysis of 20 randomized controlled trials (N=1,162) found CBT-I reduced time awake after sleep onset by 55 minutes and improved sleep efficiency from 81.4% to 88.0% at post-treatment, with gains maintained at 12-month follow-up [20].

CBT-I consists of five components: sleep restriction therapy, stimulus control, cognitive restructuring, sleep hygiene education, and relaxation training. Sleep restriction, often the most potent component, limits time in bed to the patient's current total sleep time (minimum 5.5 hours) and then expands it by 15-minute increments once sleep efficiency exceeds 85% [21].

Pharmacologic Second-Line Options

When CBT-I is unavailable or partially effective, pharmacotherapy is added. The FDA-approved options with the strongest evidence include:

• Suvorexant (Belsomra), a dual orexin receptor antagonist, 10 to 20 mg at bedtime. A phase III trial (N=1,021) published in The Lancet Neurology showed suvorexant 20 mg reduced wake after sleep onset by 22 minutes versus 4 minutes for placebo at month 3 [22].
• Lemborexant (Dayvigo) 5 to 10 mg. The SUNRISE-2 trial (N=949) demonstrated sustained efficacy at 12 months with no rebound insomnia upon discontinuation [23].
• Low-dose doxepin 3 to 6 mg (Silenor), effective specifically for sleep maintenance. Its FDA label targets a trial duration of no more than 4 weeks [24].

Benzodiazepine receptor agonists (zolpidem, eszopiclone, temazepam) carry FDA black-box warnings for complex sleep behaviors and carry substantial rebound insomnia risk on discontinuation. The AASM 2017 guideline recommends using them only for short-term bridging while CBT-I is initiated [25].

Acute Insomnia: Short-Term Disruption With a Specific Trigger

Acute insomnia lasts fewer than 3 months and is typically linked to an identifiable stressor: a medical illness, bereavement, job change, or travel. Roughly 30 to 35% of adults experience at least one episode of acute insomnia per year [26]. Most cases resolve without intervention once the stressor resolves, but approximately 15% progress to chronic insomnia [27].

Brief Behavioral Treatment for Insomnia (BBTI), a 4-session adaptation of CBT-I, reduced Insomnia Severity Index scores by 8.6 points (versus 3.0 for sleep hygiene alone) in a randomized trial (N=79) and prevented progression to chronicity in 60% of participants at 6-month follow-up [28]. For acute insomnia requiring pharmacologic support, the AASM suggests short courses (3, 5 nights) of a non-benzodiazepine hypnotic or a low dose of diphenhydramine, acknowledging limited evidence for the latter and substantial tolerance risk [25].

Obstructive Sleep Apnea and Circadian Disruption

Obstructive sleep apnea (OSA) is defined by recurrent episodes of upper-airway collapse during sleep, causing apneas and hypopneas, quantified by the apnea-hypopnea index (AHI). An AHI of 5, 14 events per hour is mild, 15, 29 moderate, and 30 or greater severe [29]. The Wisconsin Sleep Cohort Study (N=1,522) found OSA prevalence of 24% in men and 9% in women aged 30, 60, with the condition substantially underdiagnosed [30].

OSA and circadian disruption interact bidirectionally. Intermittent hypoxia from OSA disrupts SCN output, alters melatonin secretion timing, and fragments slow-wave sleep. In shift workers, circadian misalignment worsens upper-airway muscle tone during non-standard sleep periods, raising AHI by an average of 7 events per hour compared with the same individuals sleeping on a normal schedule [9].

CPAP Therapy: Evidence and Adherence

Continuous positive airway pressure (CPAP) remains the gold-standard treatment for moderate-to-severe OSA. The SAVE trial (N=2,717) published in the New England Journal of Medicine found that CPAP added to usual care did not reduce the primary composite cardiovascular outcome over 3.7 years, but did significantly improve daytime sleepiness (Epworth score reduction: 2.5 points, P<0.001), quality of life, and mood scores [31]. Subgroup analyses suggested cardiovascular benefit in patients achieving CPAP use greater than 4 hours per night.

Adherence is the central clinical problem. Approximately 46 to 83% of patients prescribed CPAP use it fewer than 4 hours per night at 1 year [32]. Behavioral interventions, including telemonitoring with motivational feedback, increase adherence by a mean of 1.1 hours per night versus standard care (meta-analysis, 15 trials, N=2,159) [33].

For patients intolerant of CPAP, mandibular advancement devices (MAD) reduce AHI by a mean of 13.6 events per hour (vs. 25.4 for CPAP) but are preferred by patients and show comparable sleepiness outcomes at moderate OSA severity [34]. Hypoglossal nerve stimulation (Inspire device) is FDA-approved for moderate-to-severe OSA with a concentric collapse pattern in CPAP-intolerant patients and reduced AHI by 68% in the STAR trial (N=126) at 12 months [35].

Restless Legs Syndrome: Circadian-Patterned Sensorimotor Disorder

Restless legs syndrome (RLS), also called Willis-Ekbom disease, affects 5 to 15% of the general population and is defined by four diagnostic criteria per the International RLS Study Group: an urge to move the legs, usually accompanied by uncomfortable sensations; worsening at rest; improvement with movement; and circadian worsening in the evening or night [36]. That fourth criterion makes RLS inherently a circadian condition. Symptoms peak between 10 PM and 4 AM, aligned with the trough of dopaminergic activity in the basal ganglia [37].

Serum ferritin below 75 ng/mL is a modifiable driver of RLS. Intravenous iron (ferric carboxymaltose 500 mg or low-molecular-weight iron dextran 1 to 000 mg) produced complete or near-complete RLS remission in 58% of patients with ferritin <75 ng/mL in the IRLS IV iron trial (N=192, 12-week follow-up) [38]. Oral iron sulfate 325 mg twice daily on an empty stomach with vitamin C 100 mg is appropriate when ferritin is 50 to 74 ng/mL and IV access is impractical [39].

Pharmacotherapy for Moderate-to-Severe RLS

The FDA-approved dopaminergic agents are pramipexole (Mirapex) 0.125 to 0.5 mg and ropinirole (Requip) 0.25 to 4 mg, both taken 1 to 3 hours before typical symptom onset. A systematic review of 7 RCTs (N=1,098) confirmed both agents reduced the International RLS Scale by at minimum 10 points versus placebo, meeting the threshold for clinically meaningful improvement [40].

Augmentation (paradoxical worsening of RLS with long-term dopamine agonist use) occurs in approximately 8% of patients per year. The 2023 AASM clinical practice guideline states: "Clinicians should consider alpha-2-delta ligands as the preferred pharmacotherapy for RLS to minimize augmentation risk" [41]. Gabapentin enacarbil (Horizant) 600 mg at 5 PM is FDA-approved and demonstrated superiority over ropinirole in a head-to-head trial (N=196 to 24 weeks) on augmentation incidence (0% vs. 9.5%, P<0.01) [42].

Non-24-Hour Sleep-Wake Disorder: The Freerunning Clock

Non-24-hour sleep-wake disorder (N24SWD) is caused by a failure of light to entrain the SCN. The clock "free-runs" at its intrinsic period (slightly longer than 24 hours), causing sleep and wake times to drift progressively later by 30 to 60 minutes each day. The condition affects 55 to 70% of totally blind individuals due to absent light perception [43]. Sighted cases are rare (prevalence <0.03%) but documented and often misdiagnosed as psychiatric illness.

Tasimelteon (Hetlioz) 20 mg at the same clock time each evening is the only FDA-approved treatment for N24SWD. The SET trial (N=84) showed tasimelteon entrained 20% of totally blind patients versus 3% on placebo (P = 0.004) and reduced nighttime awakenings by a mean of 50 minutes [44]. Melatonin 0.5 to 3 mg at a consistent clock time each night is used off-label and is cheaper, though no adequately powered RCT has confirmed entrainment in N24SWD [43].

Jet Lag Disorder: Transient Circadian Disruption

Jet lag results from rapid transmeridian travel crossing at least two time zones. Eastward travel (phase advance required) is harder to recover from than westward travel (phase delay required) because the SCN's intrinsic period exceeds 24 hours. Recovery takes roughly one day per time zone eastward and 0.5 to 0.75 days per time zone westward [45].

Melatonin 0.5 to 5 mg taken at destination bedtime for 3, 5 nights reduces jet-lag severity scores by a mean of 2.2 points on a 10-point scale versus placebo (Cochrane review, 10 trials, N=964) [46]. Short-acting hypnotics such as zolpidem 5 to 10 mg can restore sleep architecture during the adaptation window but should be avoided when the traveler must operate vehicles or machinery within 8 hours.

Pre-travel light scheduling using apps (e.g., Timeshifter, which applies published circadian-phase-shifting algorithms) reduced jet-lag symptoms in a prospective observational study (N=1,003 flight attendants) by 47% versus unstructured recovery [47].

Diagnosing All CRSWDs: A Practical Algorithmic Approach

Accurate diagnosis prevents years of mismanaged treatment. The minimum workup for any suspected CRSWD includes:

1. Two-week sleep diary recording sleep onset time, wake time, naps, and sleepiness ratings.
2. Actigraphy for at least 7 consecutive days (14 days preferred), worn on the non-dominant wrist.
3. DLMO measurement when DSPD or N24SWD is suspected (saliva or urine 6-sulfatoxymelatonin).
4. Epworth Sleepiness Scale for objective sleepiness quantification (score 0, 24; scores above 10 suggest pathologic daytime sleepiness).
5. Berlin Questionnaire or STOP-BANG for OSA screening, given high comorbidity rates.

The AASM's 2015 clinical practice guidelines specify: "The diagnosis of all CRSWD subtypes should be based on a comprehensive sleep history, circadian timing markers when available, and at minimum one week of actigraphy" [1]. Polysomnography is not required for CRSWD diagnosis but is indicated when OSA or periodic limb movement disorder is suspected concurrently.

Light Therapy: Dosing, Timing, and Device Selection

Light therapy is the single intervention that appears across nearly every CRSWD protocol. Device specifications matter. A lamp must deliver at least 2,500 lux at 50 to 60 cm from the face to produce meaningful phase shifting. Standard room lighting delivers 100, 500 lux and is insufficient. Devices emitting 10,000 lux at 30 cm (such as the Carex Day-Light Classic Plus or equivalent) can achieve a 30-minute effective session versus 1 to 2 hours for 2,500-lux devices [48].

Wavelength also matters. Short-wavelength (blue) light at 460, 480 nm maximally stimulates melanopsin-containing intrinsically photosensitive retinal ganglion cells (ipRGCs), which project directly to the SCN. A crossover trial (N=27) found that 460-nm blue light produced a 1.28-hour phase delay versus 0.38 hours for 555-nm green light at equal photon densities [49]. Blue-light blocking glasses worn after 8 PM blunt evening light's phase-delaying effect and are useful for DSPD patients who cannot avoid screens before bed [50].